Uncommon EGFR Mutations Research Overview At MOASC Spotlight 2025, Dr. Darren Wijaya, MD, from Loma Linda University Health, shared vital…
Browsing: Lung Cancer
This report examines the NSCLC HER3-DXd breakthrough. It focuses on its potential impact on patients with resistant EGFR-mutated non-small cell…
Introduction to Datopotamab Deruxtecan EGFR-Mutated NSCLC On June 23, 2025, the FDA approved Datopotamab Deruxtecan EGFR-Mutated NSCLC treatment, known as…
Tarlatamab Phase 3 Results SCLC ASCO 2025 The tarlatamab phase 3 results for SCLC, shared at ASCO 2025, showed a…
Published: June 4, 2025Category: Lung Cancer Research Introduction to Neoadjuvant Nivolumab Plus Chemotherapy in CheckMate 816 The CheckMate 816 trial…
At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell…
OncologyTube.com presents the ASCO 2025 Top 10 Abstracts, highlighting practice-changing trials in oncology. It features advancements in cancer care, from…
iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical…
Ticiana Leal, MD, a distinguished oncologist from the Winship Cancer Institute of Emory University, shared her insights during a discussion…
In a recent discussion on the long-term efficacy and safety of TT field treatment for lung cancer, Allen Wilbanks raised…
Ferdinandos Skoulidis, MD, PhD, from the MD Anderson Cancer Center, presented the results of biomarker subgroup analyses from the phase…
Dr. Atulya Khosla discussed the “Saved by the Scan” public service advertising program initiated by the American Lung Association (ALA)…
iFrame is not supported! Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at ASCO 2023 Jack West…
The Roger Li, MD discussed the updated results from the CORE1 trial, which explored the combination of Cretostimogene Grenadorepvec (CG0070),…
Lung Cancer Trials: Insights into Latest Clinical Trials in Thoracic Oncology – Expert Analysis from Ravi Salgia, MD By Ravi…
AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian…
iFrame is not supported! AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr.…
Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit…
AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian…
iFrame is not supported! Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD…
Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit…
iFrame is not supported! LCMC3 Neoadjuvant Atezolizumab Phase 2 Study Results What is the LCMC3 (Lung Cancer Mutation Consortium)…
LCMC3 Neoadjuvant Atezolizumab Phase 2 Study Results What is the LCMC3 (Lung Cancer Mutation Consortium) Trial? So, this is…
ASCO [2022] Lung Cancer In-Depth Slides: MOASC Dr. Misako Nagasaka’s (thoracic oncology) MOASC Presentation on ASCO (Annual Meeting, American…
Question and Answer Session Dr. Misako Nagasaka – ASCO [2022] Lung Cancer In-Depth Slides: MOASC Presentation https://oncologytube.com/v/41320 Misako Nagasaka, MD…
KRAS Lung Cancer: Taking on Goliath Discussion by Jai Luo MD By Jai Luo, MD Hi there, my name is…